AR

Anita Rani

Active Director Director DIN 09361041
DIN 09361041 First appointment Oct 2021 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2021
Shareholding value •••• Premium profile

About Anita Rani

Data last updated:

Anita Rani is a Director at Critico Pharma Private Limited (since 2021). The company operates in Chemicals. Critico Pharma Private Limited reported revenue of ₹32.5 Lakh (FY 2025).

DIN 09361041
Primary Designation Director
Industry Chemicals
First Appointment 14 Oct 2021
Oldest Company Age 5 yrs
Largest company Critico Pharma Private Limited · ₹32.5 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Critico Pharma Private Limited U24239TG2021PTC156003
Director14 Oct 20212021₹32.5 Lakh (FY 2025)Active

Board colleagues of Anita Rani

NameDINCompanyDesignation
Sarvajeet Pal09361040Critico Pharma Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Critico Pharma Private Limited
Premium access

Shareholding and investment profile for Anita Rani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anita Rani

Anita Rani currently holds 1 directorship: Critico Pharma Private Limited (Director, since 14 Oct 2021, revenue ₹32.5 Lakh (FY 2025)).

Anita Rani was first appointed on 14 Oct 2021 as Director at Critico Pharma Private Limited.

The current boards of Anita Rani's companies include Sarvajeet Pal (Critico Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available